FIGURE 4.

Independent factors associated with: (A) overall OAC use at discharge (monotherapy or in combination with at least one antiplatelet); (B) overall use of NOAC or VKA at discharge; (C) overall DAPT or DAT/TAT at discharge; (D) DAPT or DAT/TAT in the PCI subgroup. Lower level of normal for hemoglobin was defined as 13 g/dL for men and 12 g/dL for women. Complex PCI was defined according to the 2020 ESC NSTE-ACS management guidelines as any of: at least three stents implanted, at least three lesions treated, total stent length >60 mm, history of complex revascularization (left main, bifurcation with . two stents implanted, chronic total occlusion) or history of stent thrombosis on antiplatelet treatment. No data regarding stenting of last patent vessel was available. AF=atrial fibrillation, NSTE-ACS=non-ST elevation acute coronary syndrome, OR=odds ratio, CI=confidence interval, BMI=body mass index, OAC=oral anticoagulation, NOAC=non-vitamin K antagonist oral anticoagulant, ACS=acute coronary syndrome, PCI=percutaneous coronary intervention, VKA=vitamin K antagonist, DAPT=dual antiplatelet therapy, DAT=dual antithrombotic therapy, TAT=triple antithrombotic therapy